BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement Post author:GHIAA Admin Post published:April 25, 2022 Post category: Continue ReadingBMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
CEPI – Dynavax, COVID-19 Material Reservation Agreement Post author:GHIAA Admin Post published:January 28, 2022 Post category: Continue ReadingCEPI – Dynavax, COVID-19 Material Reservation Agreement
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement Post author:GHIAA Admin Post published:November 18, 2021 Post category: Continue ReadingModerna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement Post author:GHIAA Editor Post published:September 15, 2021 Post category: Continue ReadingCureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
CEPI – Valneva, Chikungunya Vaccine Funding Agreement Post author:GHIAA Admin Post published:August 23, 2021 Post category: Continue ReadingCEPI – Valneva, Chikungunya Vaccine Funding Agreement
BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments Post author:GHIAA Admin Post published:June 30, 2021 Post category: Continue ReadingBMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement Post author:GHIAA Admin Post published:June 30, 2021 Post category: Continue ReadingNatick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
BMGF – CureVac, Global Access Commitments Agreement Post author:GHIAA Editor Post published:June 30, 2021 Post category: Continue ReadingBMGF – CureVac, Global Access Commitments Agreement
CEPI – CureVac, Framework Partnering Agreement Post author:GHIAA Editor Post published:June 30, 2021 Post category: Continue ReadingCEPI – CureVac, Framework Partnering Agreement